Encephalopathy Connectomic Collapse Atlas (ECCA-SEP) | Septic Encephalopathy Biomarker Panel

SCF-ECCA-SEP-BIO-0005

Septic Encephalopathy Biomarker Panel

Systemic Inflammatory Connectomic Collapse Validation System

FDA-Aligned Endpoint Framework for Precision Acupuncture Planning

Encephalopathy Connectomic Collapse Atlas (ECCA-SEP)

I. PURPOSE

The SCF Septic Encephalopathy Biomarker Panel is designed to:

Establish septic encephalopathy diagnosis support
Quantify systemic inflammatory neuroconnectomic collapse
Stratify sepsis-associated neurologic injury severity
Predict delirium, coma, and mortality risk
Personalize acupuncture neurocircuit selection
Monitor ICU-to-recovery transition
Support FDA-aligned translational endpoint development
Enable precision forecasting of neuroimmune and autonomic deterioration

II. SCF SEPTIC ENCEPHALOPATHY BIOMARKER DOMAINS

Domain	Function
Sepsis Burden	Measures systemic infection severity
Neuroimmune Activation	Measures cytokine storm activity
Endothelial Injury	Measures vascular collapse
BBB Integrity	Measures neurovascular disruption
Neuroaxonal Injury	Measures neuronal damage
Glial Activation	Measures astrocyte/microglial activation
Mitochondrial Function	Measures ATP-redox collapse
Autonomic Function	Measures neuro-autonomic failure
Connectomic Function	Measures network synchronization
Cognitive Function	Measures delirium and cortical performance
Mortality Forecasting	Predicts progression and outcome

III. SEPSIS BURDEN PANEL

Tier 1 Systemic Infection Layer

Biomarker	FDA-Aligned Assay	Normal	Mild Risk	Moderate Risk	Severe Risk
Procalcitonin (PCT)	CLIA Immunoassay	<0.05 ng/mL	0.05–0.5	0.5–2.0	>2.0
CRP	hsCRP	<1 mg/L	1–10	10–100	>100
Lactate	Clinical Chemistry	<2 mmol/L	2–3	3–4	>4
WBC Count	CBC	4–11 ×10⁹/L	11–15	15–25	>25
Neutrophil-Lymphocyte Ratio	CBC Derived	<3	3–5	5–10	>10

Endpoint

Systemic Sepsis Burden Index (SSBI)

IV. CYTOKINE STORM PANEL

Tier 2 Neuroimmune Amplification Layer

Biomarker	Assay	Baseline	Mild	Moderate	Severe
IL-6	Multiplex	<2 pg/mL	2–25	25–100	>100
TNF-α	Multiplex	<5 pg/mL	5–15	15–40	>40
IL-1β	Multiplex	<1 pg/mL	1–5	5–15	>15
IL-8	Multiplex	Reference	Elevated	High	Very High
IFN-γ	Multiplex	Reference	Elevated	High	Very High

Endpoint

Cytokine Storm Severity Score (CSSS)

V. ENDOTHELIAL INJURY PANEL

Tier 3 Microvascular Collapse Layer

Biomarker	Assay	Baseline	Mild	Moderate	Severe
Angiopoietin-2	ELISA	Normal	Elevated	High	Very High
Soluble ICAM-1	ELISA	Normal	Elevated	High	Very High
Soluble VCAM-1	ELISA	Normal	Elevated	High	Very High
vWF Antigen	Immunoassay	Normal	Elevated	High	Very High
Syndecan-1	ELISA	Normal	Elevated	High	Very High

Endpoint

Endothelial Collapse Index (ECI)

VI. BBB INTEGRITY PANEL

Tier 4 Neurovascular Layer

Biomarker	Assay	Baseline	Mild	Moderate	Severe
S100B	Immunoassay	<0.1 ng/mL	0.1–0.2	0.2–0.5	>0.5
MMP-9	ELISA	<150 ng/mL	150–250	250–400	>400
Albumin Quotient	CSF/Serum	<6.5	6.5–8	8–12	>12
VEGF	ELISA	Normal	Elevated	High	Very High

Endpoint

BBB Permeability Index (BBPI)

VII. NEUROAXONAL INJURY PANEL

Tier 5 Connectomic Injury Layer

Biomarker	Assay	Baseline	Mild	Moderate	Severe
NfL	Simoa	<10 pg/mL	10–20	20–50	>50
Total Tau	Simoa	<2 pg/mL	2–4	4–8	>8
NSE	CLIA	<12 ng/mL	12–18	18–25	>25
UCH-L1	ELISA	<100 pg/mL	100–200	200–400	>400

Endpoint

Neuroaxonal Injury Index (NAII)

VIII. GLIAL ACTIVATION PANEL

Tier 6 Neuroglial Collapse Layer

Biomarker	Assay	Baseline	Mild	Moderate	Severe
GFAP	Simoa	<120 pg/mL	120–250	250–500	>500
YKL-40	ELISA	<60 ng/mL	60–100	100–150	>150
sTREM2	ELISA	Normal	Elevated	High	Very High
S100B	Immunoassay	<0.1	0.1–0.2	0.2–0.5	>0.5

Endpoint

Glial Activation Severity Score (GASS)

IX. MITOCHONDRIAL FAILURE PANEL

Tier 7 Bioenergetic Collapse Layer

Biomarker	Assay	Baseline	Mild	Moderate	Severe
Lactate	Clinical Chemistry	<2	2–3	3–5	>5
Pyruvate	LC-MS/MS	Normal	Elevated	High	Very High
Lactate/Pyruvate Ratio	LC-MS/MS	<20	20–30	30–40	>40
ATP Production Rate	Seahorse	Normal	↓10%	↓25%	↓50%

Endpoint

Bioenergetic Failure Index (BFI)

X. AUTONOMIC FAILURE PANEL

Tier 8 Neuro-Autonomic Layer

Biomarker	Assay	Baseline	Mild	Moderate	Severe
HRV SDNN	ECG	>100 ms	80–100	50–80	<50
RMSSD	ECG	>30 ms	20–30	10–20	<10
LF/HF Ratio	HRV	1–2	2–3	3–5	>5
Vasopressor Requirement	ICU Monitoring	None	Low	Moderate	High

Endpoint

Autonomic Collapse Index (ACI)

XI. CONNECTOMIC FUNCTION PANEL

Tier 9 Connectomic Collapse Layer

Biomarker	Assay	Baseline	Mild	Moderate	Severe
EEG Delta Power	qEEG	Normal	+20%	+50%	+100%
EEG Theta Excess	qEEG	Normal	Mild	Moderate	Severe
Alpha Connectivity	qEEG	Normal	↓10%	↓25%	↓50%
rs-fMRI Connectivity	MRI	↓10%	↓25%	↓50%	↓75%
DTI Fractional Anisotropy	MRI-DTI	Normal	↓5%	↓10%	↓20%

Endpoint

Connectomic Collapse Index (CCI)

XII. DELIRIUM / COGNITIVE PANEL

Tier 10 Functional Layer

Endpoint	Normal	Mild	Moderate	Severe
CAM-ICU	Negative	Intermittent	Positive	Persistent
MoCA	≥26	22–25	16–21	<16
GCS	15	13–14	9–12	≤8
Delirium Severity Score	Minimal	Mild	Moderate	Severe

Endpoint

Septic Connectomic Performance Score (SCPS)

XIII. MORTALITY FORECAST PANEL

Tier 11 Prognostic Layer

Biomarker	Low Risk	Intermediate Risk	High Risk
Lactate	<2	2–4	>4
IL-6	<10	10–50	>50
GFAP	<250	250–500	>500
NfL	<20	20–50	>50
HRV SDNN	>80	50–80	<50
GCS	15	9–14	≤8

Endpoint

Septic Mortality Forecast Index (SMFI)

XIV. SCF ACUPUNCTURE RESPONSE FORECAST PANEL

Biomarker Pattern	Predicted Dysfunction	Primary Acupuncture Network
Elevated IL-6 + TNF-α	Cytokine storm	ST36 + LI11 + LI4
Elevated GFAP + S100B	Glial-BBB injury	GV20 + ST36 + PC6
Elevated NfL + Tau	Neuroaxonal injury	GV20 + Sishencong + GB20
High Lactate/Pyruvate Ratio	Mitochondrial collapse	KI3 + SP6 + ST36
HRV suppression	Dysautonomia	PC6 + HT7 + CV17
Elevated Ang-2 + Syndecan-1	Endothelial collapse	ST36 + PC6 + CV17
Reduced EEG Connectivity	Connectomic collapse	GV20 + GV24 + Sishencong
Delirium-dominant phenotype	Cortical dysynchrony	GV20 + GV26 + Yintang

XV. SCF PRECISION FORECASTING MODEL

Low-Risk Recovery

Criteria:

Lactate <2
IL-6 <10
GFAP <250
GCS 15
Preserved HRV

Predicted Response:

High likelihood of recovery with supportive neuromodulation.

Intermediate Risk

Criteria:

Lactate 2–4
GFAP 250–500
Moderate EEG slowing
GCS 9–14

Predicted Response:

Prolonged recovery trajectory.

High-Risk Progression

Criteria:

Lactate >4
GFAP >500
NfL >50
Severe EEG slowing
GCS ≤8

Predicted Response:

High mortality and severe neurologic injury risk.

XVI. COMPOSITE SCF SEPTIC ENCEPHALOPATHY SCORE (SCF-SES)

Weighted Domains

Domain	Weight
Sepsis Burden	15%
Cytokine Storm	15%
Endothelial Injury	15%
BBB Integrity	10%
Neuroaxonal Injury	10%
Glial Activation	10%
Mitochondrial Function	10%
Connectomics	10%
Autonomics	3%
Cognition	2%

Interpretation

Score	Classification
<20	Stable
20–40	Mild Septic Connectomic Dysfunction
40–60	Moderate Collapse
60–80	Severe Septic Encephalopathy
>80	Critical Neuroimmune-Microvascular Failure

XVII. PRIMARY FDA-ALIGNED CLINICAL ENDPOINTS

Diagnostic-Support Endpoints

Procalcitonin
Lactate
CBC with differential
CAM-ICU
EEG

Predictive Endpoints

NfL
GFAP
IL-6
HRV
Angiopoietin-2

Therapeutic Response Endpoints

Reduction in lactate
Reduction in cytokine burden
Improved CAM-ICU score
Improved HRV
Improved Connectomic Collapse Index

NEXT PANEL IN SEQUENCE

SCF-ECCA-MET-BIO-0006

Metabolic Encephalopathy Biomarker Panel

(Systemic Metabolic Connectomic Collapse Validation System)

MASTER REGISTRY INDEX

SCF-ECCA-SEP-BIO-0005 — Septic Encephalopathy Biomarker Panel
SCF-ECCA-SEP-ACU-0005 — Septic Encephalopathy Acupoint Neuro-Circuit Mapping Atlas
SCF-ECCA-0001 — Encephalopathy Connectomic Collapse Atlas
SCF-BIOMARKER-ENDPOINTS-0001 — SCF Biomarker Endpoint Validation Framework
SCF-PATH-PROT-0001 — SCF Pathophysiology Protocol
SCF-ACU-NEURO-ATLAS-0001 — SCF Neural Mapping Schema